FDA: Screen genes before taking Tegretol

If you need more evidence that individualized drug therapy is the next frontier, look no further. The FDA has issued a new warning on carbamazepine, an epilepsy-slash-bipolar drug that can cause rare but severe side effects in certain patients of Asian descent. Before using the drug--marketed as Tegretol by Novartis and Equetro by Validus Pharmaceuticals--patients of Asian ancestry should undergo genetic testing, the agency said.

The black-box warning will alert patients to the potential for Stevens-Johnson syndrome and for toxic epidermal necrolysis, both severe skin reactions.

The FDA's genetic-testing recommendation is among its first. The agency previously has alerted healthcare providers to specific genetic variations and their effect on patients' response to particular drugs. A few months ago, the agency suggested that patients be tested for certain genetic variances before taking the blood thinner warfarin.

- here's the warning from the FDA
- read the report in The Wall Street Journal

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.